98 related articles for article (PubMed ID: 26296295)
1. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Azad N; Perroy A; Gardner E; Imamura CK; Graves C; Sarosy GA; Minasian L; Kotz H; Raggio M; Figg WD; Kohn EC
Cancer Biol Ther; 2009 Oct; 8(19):1800-5. PubMed ID: 19738417
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Chénard-Poirier M; Hansen AR; Gutierrez ME; Rasco D; Xing Y; Chen LC; Zhou H; Webber AL; Freshwater T; Sharma MR
Invest New Drugs; 2024 Jun; 42(3):241-251. PubMed ID: 38483782
[TBL] [Abstract][Full Text] [Related]
5. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Patnaik A; Weiss GJ; Papadopoulos KP; Hofmeister CC; Tibes R; Tolcher A; Isaacs R; Jac J; Han M; Payumo FC; Cotreau MM; Ramanathan RK
Br J Cancer; 2014 Jul; 111(2):272-80. PubMed ID: 24901237
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
Takahashi T; Boku N; Murakami H; Naito T; Tsuya A; Nakamura Y; Ono A; Machida N; Yamazaki K; Watanabe J; Ruiz-Garcia A; Imai K; Ohki E; Yamamoto N
Invest New Drugs; 2012 Dec; 30(6):2352-63. PubMed ID: 22249430
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Modjtahedi H; Cho BC; Michel MC; Solca F
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):505-21. PubMed ID: 24643470
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.
Juarez TM; Gill JM; Heng A; Carrillo JA; Wagle N; Nomura N; Nguyen M; Truong J; Dobrawa L; Sivakumar W; Barkhoudarian G; Kelly DF; Kesari S
Neurooncol Adv; 2024; 6(1):vdae049. PubMed ID: 38680990
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.
Evans L; Walker R; MacDiarmid J; Brahmbhatt H; Anazodo A; McCowage G; Gifford AJ; Kavallaris M; Trahair T; Ziegler DS
Target Oncol; 2024 May; 19(3):333-342. PubMed ID: 38546944
[TBL] [Abstract][Full Text] [Related]
10. Potential of afatinib in the treatment of patients with HER2-positive breast cancer.
Geuna E; Montemurro F; Aglietta M; Valabrega G
Breast Cancer (Dove Med Press); 2012 Aug; 4():131-7. PubMed ID: 24367201
[TBL] [Abstract][Full Text] [Related]
11. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
Gunzer K; Joly F; Ferrero JM; Gligorov J; de Mont-Serrat H; Uttenreuther-Fischer M; Pelling K; Wind S; Bousquet G; Misset JL
Springerplus; 2016; 5():45. PubMed ID: 26835225
[TBL] [Abstract][Full Text] [Related]
13. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
[TBL] [Abstract][Full Text] [Related]
15. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
16. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
17. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
[TBL] [Abstract][Full Text] [Related]
18. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Bahleda R; Hollebecque A; Varga A; Gazzah A; Massard C; Deutsch E; Amellal N; Farace F; Ould-Kaci M; Roux F; Marzin K; Soria JC
Br J Cancer; 2015 Nov; 113(10):1413-20. PubMed ID: 26512876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
